Drug Profile
Research programme: xenotransplants - Lung Biotechnology/Viridos
Latest Information Update: 29 Sep 2021
Price :
$50
*
At a glance
- Originator Lung Biotechnology; Synthetic Genomics
- Developer Lung Biotechnology; Viridos
- Class Cell therapies
- Mechanism of Action Cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Lung disorders; Renal failure
Most Recent Events
- 27 Sep 2021 Synthetic Genomics is now called Viridos
- 28 Oct 2019 No recent reports of development identified for preclinical development in Lung-disorders in USA (Implant)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Renal-failure in USA (Implant)